CADL vs. PSTX, GLUE, ADAP, STRO, IVVD, FENC, CHRS, AVXL, URGN, and AGEN
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Poseida Therapeutics (PSTX), Monte Rosa Therapeutics (GLUE), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Invivyd (IVVD), Fennec Pharmaceuticals (FENC), Coherus BioSciences (CHRS), Anavex Life Sciences (AVXL), UroGen Pharma (URGN), and Agenus (AGEN). These companies are all part of the "medical" sector.
Poseida Therapeutics (NASDAQ:PSTX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.
Poseida Therapeutics currently has a consensus target price of $14.67, indicating a potential upside of 441.21%. Candel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 1.57%. Given Candel Therapeutics' higher probable upside, research analysts plainly believe Poseida Therapeutics is more favorable than Candel Therapeutics.
Candel Therapeutics has lower revenue, but higher earnings than Poseida Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Poseida Therapeutics had 5 more articles in the media than Candel Therapeutics. MarketBeat recorded 6 mentions for Poseida Therapeutics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.46 beat Poseida Therapeutics' score of 0.00 indicating that Poseida Therapeutics is being referred to more favorably in the media.
Poseida Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500.
46.9% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 2.1% of Poseida Therapeutics shares are owned by insiders. Comparatively, 44.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Poseida Therapeutics received 25 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 64.71% of users gave Poseida Therapeutics an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Candel Therapeutics has a net margin of 0.00% compared to Candel Therapeutics' net margin of -190.76%. Candel Therapeutics' return on equity of -94.90% beat Poseida Therapeutics' return on equity.
Summary
Poseida Therapeutics beats Candel Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
